The University of Bristol spinout is working on adapting cell therapies to solid tumours.
Adam Perriman, professor of bioengineering at University of Bristol, is every tech transfer professional’s dream faculty member. He gained his PhD from Australian National University in 2007 – not long before the global financial crisis threw the world’s economies into turmoil – and immediately began pondering the benefits of spinouts, which were still a rarity at the time.
“Things were looking rough in 2008,” he told Global University Venturing. “I was looking at the world and realised that the west does not really have anything left. If we do not start commercialising all this science – and very little was making it out beyond publishing at the time – then where does the value lie?”
Although long proven right, with spinouts an increasingly important component of knowledge transfer across the world, it would take almost a decade before Perriman found his own perfect opportunity in 2017: CytoSeek. He came up…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
